title: Mitochondria-Targeted Antioxidant SkQR1 Reduces TNF-Induced Endothelial Permeability in vitro.
abstract: Prolonged or excessive increase in the circulatory level of proinflammatory tumor necrosis factor (TNF) leads to abnormal activation and subsequent damage to endothelium. TNF at high concentrations causes apoptosis of endothelial cells. Previously, using mitochondria-targeted antioxidants of SkQ family, we have shown that apoptosis of endothelial cells is dependent on the production of reactive oxygen species (ROS) in mitochondria (mito-ROS). Now we have found that TNF at low concentrations does not cause cell death but activates caspase-3 and caspase-dependent increase in endothelial permeability in vitro. This effect is probably due to the cleavage of β-catenin - an adherent junction protein localized in the cytoplasm. We have also shown that extracellular matrix metalloprotease 9 (MMP9) VE-cadherin shedding plays a major role in the TNF-induced endothelial permeability. The mechanisms of the caspase-3 and MMP9 activation are probably not related to each other since caspase inhibition did not affect VE-cadherin cleavage and MMP9 inhibition had no effect on the caspase-3 activation. Mitochondria-targeted antioxidant SkQR1 inhibited TNF-induced increase in endothelial permeability. SkQR1 also inhibited caspase-3 activation, β-catenin cleavage, and MMP9-dependent VE-cadherin shedding. The data suggest that mito-ROS are involved in the increase in endothelial permeability due to the activation of both caspase-dependent cleavage of intracellular proteins and of MMP9-dependent cleavage of the transmembrane cell-to-cell contact proteins.
authors.affiliation: Lomonosov Moscow State University, Belozersky Institute of Physico-Chemical Biology, Moscow, 119991, Russia. galkin.ivan.i@gmail.com.
authors.forename: I I
authors.initials: II
authors.lastname: Galkin
authors.forename: O Yu
authors.initials: OY
authors.lastname: Pletjushkina
authors.forename: R A
authors.initials: RA
authors.lastname: Zinovkin
authors.forename: V V
authors.initials: VV
authors.lastname: Zakharova
authors.forename: B V
authors.initials: BV
authors.lastname: Chernyak
authors.forename: E N
authors.initials: EN
authors.lastname: Popova
mesh_terms: D015703:Antigens, CD / Q000378:metabolism; D000975:Antioxidants / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D015820:Cadherins / Q000378:metabolism; D002199:Capillary Permeability / Q000187:drug effects*; D053148:Caspase 3 / Q000378:metabolism; D053453:Caspase 9 / Q000378:metabolism; D002460:Cell Line; D042783:Endothelial Cells / Q000166:cytology / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000166:cytology / Q000378:metabolism*; D006801:Humans; D008928:Mitochondria / Q000378:metabolism; D010971:Plastoquinone / Q000031:analogs & derivatives* / Q000494:pharmacology; D012235:Rhodamines / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000493:pharmacokinetics*; D000099152:Cadherin 5
chemical_list: D015703:Antigens, CD; D000975:Antioxidants; D015820:Cadherins; D053148:Caspase 3; D053453:Caspase 9; D010971:Plastoquinone; D012235:Rhodamines; D014409:Tumor Necrosis Factor-alpha; D000099152:Cadherin 5; C534903:10-(6'-plastoquinonyl) decylrhodamine 19; C505407:CASP3 protein, human; C506433:CASP9 protein, human